Products for Research Use Only

α, β-Methylene-ATP

CAT: 0804-HY-134440ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-134440ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
α, β-Methylene-ATP is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α, β-Methylene-ATP can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC) ; this effect can be blocked by the P2X antagonist PPADS. α, β-Methylene-ATP also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α, β-Methylene-ATP can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system[1][2][3].
CAS Number
7292-42-4
UNSPSC
12352005
Target
P2X Receptor
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/α-β-methylene-atp.html
Solubility
10 mM in DMSO
Smiles
OP(OP(CP(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1)(O)=O)(O)=O)(O)=O
Molecular Formula
C11H18N5O12P3
Molecular Weight
505.21
References & Citations
[1]Arribas-Blázquez M, et al. Overexpression of P2X3 and P2X7 Receptors and TRPV1 Channels in Adrenomedullary Chromaffin Cells in a Rat Model of Neuropathic Pain. Int J Mol Sci. 2019 Jan 3;20 (1) .|[2]Hanna RL, et al. alpha, beta-Methylene ATP elicits a reflex pressor response arising from muscle in decerebrate cats. J Appl Physiol (1985) . 2002 Sep;93 (3) :834-41.|[3]Fukui M, et al. Involvement of locus coeruleus noradrenergic neurons in supraspinal antinociception by alpha, beta-methylene-ATP in rats. J Pharmacol Sci. 2004 Feb;94 (2) :153-60
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported